Document:

EX-10.2

 Exhibit 10.2 

ACHIEVE PHARMA UK LIMITED 

August 1, 2017 
 Anthony Clarke 

Scots Grove House 
 Uxmore Road 

Checkendon 
 R98 0TD 

United Kingdom 
 Dear Tony: 

Achieve Pharma UK Limited (the “Company”) is pleased to offer you employment on the terms set out below and contained in Exhibit A and Exhibit
B attached. 
 This employment agreement (the “Agreement”) is entered into by and between you and the Company. 

 

	1.	Position. 

  

	 	1.1	Your initial title will be President and Chief Scientific Officer. While you serve as President and Chief Scientific Officer, you will also serve on the Board. This is a full-time position. In addition to your role with
the Company, based wholly in the UK, you have been appointed as a Director of Achieve Life Sciences, Inc. (the “Parent Company”) 

You shall report directly to the Chairman and Chief Executive Officer of the Company. You shall have such duties, authority and
responsibilities that are commensurate with being a director of the Parent Company and the Employer. 
  

	 	1.2	Whilst you are employed by the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that, in the reasonable
opinion of the Company, would create a conflict of interest with the Company. It is understood between you and the Company that you may continue your work with Ricanto Limited so long as you dedicate a minimum of 40 hours per week to the Company. By
signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company or any Group Company. 

 

	 	1.3	You agree, without being entitled to further remuneration, to perform duties for any Group Company. During your employment you must at all times: 

 

	 	(a)	use your best endeavours to promote the success, interests and reputation of the Group giving at all times the full benefit of your knowledge, experience, expertise and skill; 

 

	 	(b)	faithfully and diligently to the best of your ability exercise such powers and perform such duties in relation to the Group as the Board from time to time may require; 

 

	 	(c)	provide overall direction for the Company in order for it to implement agreed strategies in order to meet Company goals and objectives; 

	 	(d)	make create and sustain the organizational culture and environment needed to achieve objectives and results and recruit and retain a high performance operating team; 

 

	 	(e)	oversee the management and administration of the Company; 

  

	 	(f)	comply with your duties under the Companies Act 2006 (as amended from time to time) and similar legislation worldwide and any policy of the Company from time to time relating to dealings in shares, debentures or other
securities of the Company or any Group Company, any unpublished price sensitive information, or market abuse; 

  

	 	(g)	comply with all laws and policies of the Company, including those relating to anti-bribery and corruption; 

  

	 	(h)	not do anything that would cause you to be disqualified from continuing to act as a director of the Company or any Group Company; 

  

	 	(i)	not resign from your office of director of the Company or any Group Company without the consent of the Company, and at the written request of the Board, immediately resign from all and any directorships and other
offices held in the Company and any Group Company. 

  

	2.	Compensation. 

  

	 	2.1	The Company will pay you a starting salary at the rate of $420,000 USD per year which shall accrue day to day and be payable in equal monthly instalments in arrears in accordance with the Company’s standard payroll
schedule. Your salary will be subject to annual review. 

  

	 	2.2	In addition, you will be eligible for an incentive bonus of up to 40% of your base salary for each fiscal year of the Company, based on the achievement of performance objectives to be mutually agreed upon by you and the
Board each year. Any bonus for the fiscal year in which your employment begins will be prorated, based on the number of days you are employed by the Company during that fiscal year. Any bonus for a fiscal year will be paid within 2 1⁄2 months after the close of that fiscal year, but only if you are still employed by the Company at the time of payment. However, if you are terminated Without
Cause after the fiscal year end and your Termination Date is prior to the day when the bonus is paid, you are eligible for any accrued, unpaid bonuses earned by you (provided that any such bonus has been awarded by the Board). The Board or the
Compensation Committee may, in its sole discretion, determine not to award a bonus or to award a bonus at less than maximum eligibility. You acknowledge that a Bonus is neither required nor guaranteed by this Agreement. The determinations of the
Board (based on the recommendations of the Compensation Committee) with respect to your bonus will be final and binding. 

  

	 	2.3	The above amounts will be paid to you in USD or GBP calculated based on monthly average exchange rates. 

  

	 	2.3	By entering into this employment contract, you consent to the deduction from your salary and any bonus (or any sum due from the Company or any Group Company) any sums that you owe to the Company or any Group Company
from time to time and agree to make payment to the Company or any Group Company of any sums owed by you to the Company or any Group Company upon demand by the Company at any time. This sub Clause is without prejudice to the right of the Company and
any Group Company to recover any sums or balance of sums owed by you to the Company or any Group Company by legal proceedings. 

  
 -2- 

	3.	Employee Benefits. 

  

	 	3.1	As a regular employee of the Company, you will be eligible to participate in regular health insurance and other employee benefit plans established by the Company for its employees from time to time. 

 

	 	3.2	In addition, you will be eligible for paid time off (“PTO”) in accordance with the Company’s PTO policy, as in effect from time to time (please see your annual leave allowance as set out in Exhibit B).

  

	 	3.3	The Company may be required to arrange for you to have pension scheme membership in accordance with Chapter 1 of Part 1 of the Pensions Act 2008. If you become a member of a pension scheme, the Company shall be entitled
to deduct pension contributions from your salary and pay them to the administrator of the pension scheme on behalf of you in accordance with the pension scheme rules. 

 

	 	3.4	The Company reserves the right to change or otherwise modify, in its sole discretion, your right to receive any of the employee benefits set out in this clause 3, the terms of the policies and schemes referred to in
this clause 3, and the amount of your benefit. Your participation in any health insurance, pension scheme or other employee benefit plan shall be subject at all times to the rules of the relevant scheme from time to time in force and your
participation in any insurance scheme being at a premium that the Company considers reasonable. In the event an insurer refuses to provide you with any benefit under an insurance scheme, you agree that you shall have no right of action against the
Company in respect of such refusal. 

  

	4.	Indemnification. 

  

	 	4.1	The Company, its Parent Company and all its subsidiary companies shall indemnify you in respect of any liabilities you incur as a result of the duties carried out in the course of your employment to the maximum extent
permitted by applicable law and the Company’s certificate of incorporation and bylaws. 

  

	 	4.2	During your employment, the Company shall maintain officers’ liability insurance for your benefit on terms and conditions no less favourable than the terms and conditions generally applicable to the Company’s
other senior executive officers. 

  

	 	4.3	The Company’s obligations under this Section 4 shall survive your cessation of employment and also the termination or expiration of this letter agreement for a period of up to 6 years. 

 

	5.	Confidentiality. 

  

	 	5.1	As an employee of the Company, you will have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the
property of the Company. To protect the interests of the Company, you will need to sign the Company’s standard “Employee Agreement Regarding Confidential Information and Intellectual Property,” a copy of which is attached hereto as
Exhibit B, as a condition of your employment. 

  
 -3- 

	 	5.2	We wish to impress upon you that we do not want you to, and we hereby direct you not to, bring with you any confidential or proprietary material of any former employer or to violate any other obligations you may have to
any former employer. 

  

	 	5.3	During the period that you render services to the Company, you agree to not engage in any employment, business or activity that is in any way competitive with the business or proposed business of the Company. You will
disclose to the Company in writing any other gainful employment, business or activity that you are currently associated with or participate in that competes with the Company. You will not assist any other person or organization in competing with the
Company or in preparing to engage in competition with the business or proposed business of the Company. 

  

	6.	No Breach of Obligations to Prior Employers. 

  

	 	6.1	You warrant that by signing this employment contract and the agreement at Exhibit B, that your commencement of employment with the Company will not violate any agreement currently in place between yourself and current
or past employers. 

  

	7.	Employment Relationship and Notice of Termination. 

  

	 	7.1	Your employment with the Company is for no specific period of time. 

  

	 	7.2	Subject to clauses 8 and 9, your employment with the Company shall be subject to termination by either party giving to the other 1 month prior notice in writing (or, in the case of the Company giving notice, 1 month or
the statutory minimum, whichever is the longer period). Any period of notice shall commence immediately when it is given, irrespective of the time or date of receipt. 

 

	 	7.3	The Company may at any time in its absolute discretion elect to terminate your employment forthwith and with immediate effect by notifying you in writing that: 

 

	 	(a)	your employment is being terminated in exercise of this right, 

  

	 	(b)	the date upon which your employment is so terminated, and 

  

	 	(c)	the fact that you shall be entitled to receive in lieu of the notice period (or part thereof) an amount that shall be equivalent to your basic salary, or a combination of both, all at the Company’s sole and
absolute discretion. 

  

	 	  	If the Company exercises its right to make you a payment in lieu of notice, the Company will make the payment to you within 28 days of the termination of your employment. Any such payment will be subject to such
deductions for tax and national insurance as are required by law. 

  

	8.	Summary termination 

  

	 	8.1	Notwithstanding the provisions of clause 7 and 9, the Company may by written notice terminate your employment with immediate effect if you: 

 

	 	(a)	substantially and wilfully failure to perform your duties and responsibilities to the Company or any Group Company; 

  

	 	(b)	you deliberately violate a Company or Group Company policy; 

  
 -4- 

	 	(c)	you commission an act of fraud, embezzlement, dishonesty or any other wilful misconduct that has caused or is reasonably expected to result in material injury to the Company or any Group Company; 

 

	 	(d)	you use or disclose any Confidential Information or trade secrets of the Company or any Group Company or any other party to whom the Company or a Group Company owes an obligation of nondisclosure in circumstances where
you are unauthorised to do so; 

  

	 	(e)	you wilfully breach any of your obligations under any written agreement or covenant with the Company or any Group Company; 

  

	 	(f)	resigns as a director of the Company without the written consent of the Board or is disqualified from holding office as a director; 

  

	 	(g)	is convicted of a criminal offence (excluding an offence under road traffic legislation); 

  

	 	(h)	is made the subject of a bankruptcy order or has a receiving order or an administration order made against him; 

  

	 	(i)	becomes addicted to or is habitually under the influence of alcohol or any drug (not being a drug prescribed for you by a medical practitioner) the possession of which is controlled by law; 

 

	 	(j)	becomes a patient within the meaning of the Mental Health Act 1983; or 

  

	 	(k)	fails to comply any applicable laws, regulations, rules and codes of conduct in relation to share dealing, market abuse, bribery or corruption. 

 

	9.	Termination on Account of Illness or Injury 

  

	 	9.1	Without prejudice to clause 7 and clause 8, if you become unable to perform your duties properly by reason of illness or injury for a period or periods aggregating at least 26 weeks in any period of 12 consecutive
calendar months, then the Company may, by not less than 3 months’ prior written notice, terminate your employment. The Company agrees to withdraw any notice of termination given under this clause 9 if during the currency of the notice you
return to your full time duties and provide a medical practitioner’s certificate satisfactory to the Board that confirms that you have recovered fully in your health and no recurrence of the illness or injury can be reasonably anticipated.

  

	10.	Garden Leave 

  

	 	10.1	Without prejudice to the provisions of clauses 7-9, the Company may at any time during your employment, require you to cease performing all or any of your duties for such period
or periods of time as the Company shall in its absolute discretion determine (the “Garden Leave”). Notice provided by the Company of Garden Leave shall include the duration of such leave, where reasonably practicable. During any
such period of Garden Leave: 

  

	 	(a)	the Company shall continue to pay you your salary and shall provide you with all benefits to which you are entitled under this employment contract; 

 

	 	(b)	the Company shall be under no obligation to provide you with any work and shall be entitled to appoint any other person or persons to perform your duties under this employment contract; 

  
 -5- 

	 	(c)	you shall not, without the prior written consent of the Company, enter into or attend any Company premises or contact any employees, officers, customers, clients, agents or suppliers of the Company without its prior
permission; 

  

	 	(d)	you shall, at the request of the Company, immediately deliver to the Company all property in your possession or control that belongs to the Company or which relates to the business of the Company; 

 

	 	(e)	you shall keep the Company updated of your whereabouts so that you can be called upon to perform appropriate duties as required by the Company; and 

 

	 	(f)	for the avoidance of doubt, you shall continue to be bound by all of your obligations under this employment contract insofar as they are compatible with you being on garden leave including, without limitation, your duty
of good faith to the Company. 

  

	11.	Qualifying Termination 

 11.1    In the event of a Qualifying
Termination you will be eligible for the following benefits if at that time (i) the Company has completed one or more financing(s) totalling a minimum of US$10 million in gross proceeds; or (ii) 12 months has passed from the execution date
of this Agreement: 
  

	 	(a)	Severance Benefits. 

  

	 	(i)	The Company shall pay you 12 months of your monthly base salary (at the rate in effect immediately prior to the Separation) (the “Severance Payment”). 

 

	 	(ii)	You will receive your Severance Payment as a lump-sum, subject to any lawful deductions for tax, national insurance contributions or otherwise. The Severance Payment will be paid
in accordance with the Company’s standard payroll procedures which will be made on the next regular payroll date occurring after the Company has received a Settlement Agreement that complies with clause 13.1 from you. 

 

	 	(b)	Benefits 

  

	 	(ii)	The Company shall pay the full amount for the continuation of any employer-provided health benefits that it, in its sole discretion, decides to extend after the Termination Date. 

 

	 	(ii)	Notwithstanding the foregoing, instead of continuing to provide you with health benefits under clause 11.1(b) (i) above, the Company may in its sole discretion choose to pay you a sum (whether as a lump sum or in
instalments) in respect of any health insurance benefit that you sacrifice as a result of the termination of your employment. Any such sum will be subject to income tax and national insurance contributions and will take into account the premium paid
by the Company in respect of your participation in its healthcare schemes in the month prior to your Separation. Any such payments under this clause 11.1(b)(ii) shall commence on the later of: 

 

	 	(1)	the first day of the month following the month in which you experience a Separation; and 

  
 -6- 

	 	(2)	the date that the Company decides that you will receive a sum under this clause 11.1(b)(ii). 

Any payments under this clause 11.1(b) (ii) shall end on the earlier of: 

 

	 	(1)	the date on which you become covered by an insurance plan of a subsequent employer that the sums paid under this clause 11.1(b)(ii) are intended to cover; and 

 

	 	(2)	the last day of the period that you are paid severance benefits pursuant to clause 11.1(a) after the Separation. 

  

	 	(c)	Equity Awards 

  

	 	(i)	Each of your then outstanding Equity Awards, including awards that would otherwise vest only upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as to an additional 12 months as
if you had continued service during that time. 

  

	 	(ii)	Subject to clause 13.1, the accelerated vesting described above shall be effective as of the Separation. 

You acknowledge and agree that you may waive the rights to the benefits contained in this Section 11 by a separate mutual written consent.

  

	12.	Corporate Qualifying Termination 

 12.1    If a Corporate Qualifying
Termination occurs then you will be entitled to the following benefits: 
  

	 	(a)	Severance Benefits 

  

	 	(i)	The Company or its successor shall pay you 15 months of your monthly base salary (at the rate in effect immediately prior to the actions that resulted in the Separation) plus 100% of your target annual bonus for the
year in which the Separation occurs (the “Corporate Severance Payment”). 

  

	 	(ii)	You will be paid the Corporate Severance Payment as a lump sum payment in accordance with the Company’s standard payroll procedures on the next regular payroll date occurring after the Company has received a
Settlement Agreement from you that complies with clause 13.1. The Corporate Severance Payment will be subject to any lawful deductions for income tax, national insurance contributions or otherwise. 

 

	 	(b)	Benefits 

  

	 	(i)	 The conditions concerning employer-provided health benefits or a monetary equivalent set out at
clause 11.1(b) above shall 

  
 -7- 

	 	
apply on the same terms to you, for the same period that you are paid severance benefits pursuant to Section 12(a) following your Separation or, if earlier, until you are eligible to be
covered under another substantially equivalent medical insurance plan by a subsequent employer. 

  

	 	(c)	Equity Awards 

  

	 	(i)	Each of your then outstanding Equity Awards, including awards that would otherwise vest only upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as to 100% of the then unvested
shares subject to the Equity Award. 

  

	 	(ii)	Subject to clause 13.1 the accelerated vesting described above shall be effective as of the Separation. 

  

	13.	Additional Termination Provisions. 

  

	 	13.1	Settlement Agreement 

  

	 	  	The provisions of clauses 11 and 12 shall not apply unless: 

  

	 	(a)	you have entered into a legally binding settlement agreement with the Company in respect of all known and unknown claims that you may then have against the Company or any Group Company or any persons affiliated with the
Company or any Group Company (the “Settlement Agreement”); 

  

	 	(b)	you have complied with the terms of the Settlement Agreement; 

  

	 	(c)	you have delivered an executed copy of the Settlement Agreement to the Company within the time period specified in the Settlement Agreement; 

 

	 	(d)	the Settlement Agreement is in the form prescribed by the Company, without alterations; and 

  

	 	(e)	the Settlement Agreement complies with the statutory requirements for waiver of employment-related claims at the date it is entered into. 

 

	 	13.2	Accrued Compensation and Benefits 

  

	 	(a)	Notwithstanding anything to the contrary in Section 11 and 12 above, in connection with any termination of employment, the Company shall pay your earned but unpaid base salary and other vested but unpaid cash
entitlements for the period through and including the Termination Date (as required by law or any applicable Company plan or policy), including unused earned vacation pay and unreimbursed documented business expenses incurred by you through and
including the Termination Date (the “Accrued Compensation and Expenses”). 

  

	 	(b)	In addition, you shall be entitled to any other vested benefits earned by you for the period through and including the Termination Date under any other employee benefit plans and arrangements maintained by the Company,
in accordance with the terms of such plans and arrangements, except as modified herein (collectively “Accrued Benefits”). 

  
 -8- 

	 	(c)	Any Accrued Compensation and Expenses to which you are entitled shall be paid to you as soon as administratively practicable after the termination and, in any event, no later than two and
one-half (2-1/2) months after the end of the taxable year in which the Termination Date occurs. Any Accrued Benefits which you are entitled shall be paid to you as
provided in the relevant plans and arrangements. Any Accrued Compensation and Expenses and any Accrued Benefits to which you are entitled shall be subject to any lawful deductions for tax, national insurance or otherwise. 

 

	 	(d)	For the avoidance of doubt, in no event shall you receive payment under both Section 11 and Section 12. 

  

	14.	Tax 

  

	 	14.1	All compensation and benefits payable to you under this agreement or as a result of your employment with the Company shall be subject to such lawful deductions for tax, national insurance contributions or otherwise.

  

	 	14.2	You are encouraged to obtain your own tax advice regarding your compensation from the Company. 

  

	 	14.2	You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax
liabilities arising from your compensation. 

  

	15.	Interpretation, Amendment and Enforcement. 

  

	 	15.1	This letter agreement, together with its two exhibits, supersede and replace any prior agreements, representations or understandings (whether written, oral, implied or otherwise) between you and the Company and
constitute the entire agreement between you and the Company regarding the subject matter set forth herein. 

  

	 	15.2	This letter agreement may not be subject to material amendment or modification, except by an express written agreement signed by both you and a duly authorized officer of the Company. 

 

	 	15.3	The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter
agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by the laws of England and Wales. 

 

	 	15.4	You and the Company submit to the exclusive personal jurisdiction of the laws of England and Wales in connection with any Dispute or any claim related to any Dispute. 

  
 -9- 

	16.	Definitions. 

 The following terms have the meaning set forth below wherever they are
used in this letter agreement: 
  

			
	“Associated Company”	  	means a company or undertaking (which is not a Subsidiary or Holding Company of the Company or a Group Company) of which more than 20 per cent of the equity share capital is for the time being owned by the Company or a Group
Company or which for the time being owns more than 20 per cent of the equity share capital of the Company or a Group Company;
		
	“Board”	  	shall mean the board of directors of the Company;
		
	“Cause”	  	 shall mean:
  

i.   your substantial failure to perform your duties and responsibilities to the Company or any
Group Company or your deliberate violation of a Company or Group Company policy; 

  

ii.  your commission of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused
or is reasonably expected to result in material injury to the Company or any Group Company;
  

iii.   your unauthorized use or disclosure of any Confidential Information or trade secrets of the
Company or any Group Company or any other party to whom the Company or a Group Company owes an obligation of nondisclosure; or
  

iv.   your wilful breach of any of your obligations under any written agreement or covenant with the
Company or any Group Company.
  
 The determination as to whether
your service is being terminated for Cause shall be made in good faith by the Company and shall be final and binding.
  

The foregoing definition does not in any way limit the Company’s ability to terminate your employment at any time as provided in
clauses 7, 8 or 9.

		
	“Corporate Transaction”	  	 shall occur in the following circumstances:
  

i.   any Person becomes the Beneficial Owner directly or indirectly of securities of the Company
representing more than fifty percent (50%) of the total voting power represented by the Company’s then-outstanding voting securities provided that the acquisition of additional securities by any one Person who is considered to own more than
fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction;
  

ii.  the consummation of the sale or disposition by the Company of all or substantially all of the
Company’s assets;

  
 -10- 

			
		  	  
 iii.   the
consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity
or its parent outstanding immediately after such merger or consolidation;
  

iv.   any other transaction which qualifies as a “corporate transaction” wherein the
shareholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares of the capital stock of the Company); or

 
 v.  a change in the effective control
of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior
to the date of the appointment or election. If any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Corporate Transaction. For purposes
of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company;

 
      provided that
the transaction (including any series of transactions) also qualifies as a change in control event under U.S. Treasury Regulation 1.409A-3(i)(5);

		
	 “Corporate Qualifying

Termination”
	  	occurs when there is a Separation within twelve (12) months following a Corporate Transaction which results from (i) the Company or its successor terminating your employment for any reason other than Cause or
(ii) circumstances where you Voluntarily Resigned from your employment for Good Reason. A Separation arising from your death or disability shall not constitute a Corporate Qualifying
Termination;

  
 -11- 

			
		
	“Equity Awards”	  	means all options to purchase shares of Company common stock, including the option, as well as any and all other stock-based awards granted to you, including but not limited to stock bonus awards, restricted stock, restricted stock
units or stock appreciation rights;
		
	“Good Reason”	  	 shall arise when the Company does one of the following acts without your consent:

 
 i.   materially reduces your
level of responsibility and/or scope of authority(although a change in responsibility shall not be deemed to occur solely because you are part of a larger organization or solely because you are given a change in job title);

 
 ii.  reduces your base salary, other
than in circumstances where generally all of the executive officers of the Company have had their salary reduced to a similar extent;
  

iii.   relocates your principal workplace by more than thirty-five (35) miles from your then
current place of employment;

		
	“Group”	  	 means
  

i.   the Company;
  

ii.  any Holding Company for the time being of the Company;

 
 iii.   any Subsidiary for the
time being of the Company or of the Company’s Holding Company
  

iv.   any Associated Company, and

 
 v.  any other company or body
corporate or other form of business entity the name of which is notified in writing to you as being a member of the Group.

		
	“Group Company”	  	means any member of the Group other than the Company from time to time (including but not limited to the Parent Company);
		
	 “Holding Company”

and “Subsidiary”
	  	have the meanings given to them respectively in section 1159 of the Companies Act 2006;
		
	“Qualifying Termination”	  	 occurs when there is a Separation that is not a Corporate Qualifying Termination, in circumstances where either:

 
 i.   the Company has terminated
your employment for a reason other than Cause; or
  

ii.  you have Voluntarily Resigned from your employment for Good
Reason;

  
 -12- 

			
		  	  
 provided at all times that the termination of your employment is not
due to your death or disability;

		
	“Separation”	  	 occurs when both parties anticipate at the Termination Date that either:

 
 i.   you will not perform any
further services for the Company after the Termination Date; or
  

ii.  the level of services that you are required to perform for the Company after the Termination Date
(whether as an employee or as an independent contractor) is no more than 20% of the average level of services that you provided for the Company over the previous 36 months;

		
	“Termination Date”	  	the date that your employment with the Company comes to an end;
		
	“Voluntary Resigned”	  	 occurs when all of the following requirements have been satisfied:
  

i.   you have provided notice to the Company of your intent to assert Good Reason (the “Good
Reason Notice”) within sixty (60) days of you becoming aware that one or more of the conditions giving rise to a Good Reason exists;
  

ii.  after thirty (30) days of serving the Good Reason Notice (the “Company Cure
Period”), the Company has not remedied the condition(s) giving rise to a Good Reason; and
  

iii.   you have served notice to terminate your employment with the Company within ten
(10) days of the earlier of
  

     (a) the expiration of the Company Cure Period, and

 
      (b) the
date that the Company otherwise serves notice on you that it will not undertake to remedy the condition(s) giving rise to the Good Reason.
  

For the avoidance of doubt, in the event the Company remedies the condition giving rise to the Good Reason during the Company Cure Period, if you continue to
terminate your employment with the Company, you will not be entitled to receive any of the benefits outlined at clauses 11 or 12 of this employment contract. Furthermore, should the Company remedy the condition giving rise to the Good Reason
and then one or more of the conditions arises again within twelve (12) months following the occurrence of a Corporate Transaction, you may assert Good Reason again subject to all of the conditions set out in this employment
contract.

  
 -13- 

 We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and
accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Employee Agreement Regarding Confidential Information and Intellectual Property and returning them to me. 

If you have any questions, please call me. 
  

	
	 Very truly yours
  

ACHIEVE PHARMA UK LIMITED

	
	/s/ Richard Stewart
	
	By: Richard Stewart
	
	Title: Chairman & Chief Executive Officer

  

	
	I have read and accept this employment offer:
	
	/s/ Anthony Clarke
	Signature of Anthony Clarke

  

			
	Dated:	 	May 22, 2018

 Attachment 
 Exhibit A:
Statement of Particulars for the purpose of section 1 Employment Rights Act 1996 
 Exhibit B: Employee Agreement Regarding Confidential Information and
Intellectual Property 

  
 -14- 

 EXHIBIT A 

Statement of Particulars for the purpose of section 1 Employment Rights Act 1996 

The following information is given to supplement the information given in the body of the employment contract and to comply with the
requirements of section 1 Employment Rights Act 1996: 
  

			
	Name of employer	  	Achieve Pharma UK Limited (the “Company”)
		
	Name of employee	  	Anthony Clarke
		
	Date on which the employment began	  	1 August 2017
		
	Date of commencement of continuous employment	  	1 August 2017
		
	Rate and intervals of pay	  	US$420,000 per annum, payable in equal monthly instalments in arrears
		
	Notice of termination of employment to be given by the employer	  	1 month or the statutory minimum, whichever is the longer
		
	Notice of termination of employment to be given by the employee	  	1 month or the statutory minimum, whichever is the longer
		
	Employee’s job title	  	President and Chief Scientific Officer
		
	Employee’s place of work	  	You will work at the Henley office or anywhere else required for the Board for the proper performance of your duties. You agree to undertake such journeys in the United Kingdom and elsewhere as the Board shall require.
		
	Collective agreements which directly affect the terms and conditions of the employment	  	None
		
	Hours of work	  	Your working time will be determined exclusively by you and will change to suit business needs. As such, you agree that you fall within Regulation 20(1) of the Working Time Regulations 1998 so that you are not affected by the limit
on weekly working time contained in Regulation 4(1) of the Working

  
 -15- 

			
		  	Time Regulations 1998. If this is not the case, by entering into this employment contract you agree that the limit in Regulation 4(1) shall not apply to you, so that your working time (including overtime) may exceed an average of 48
hours for each 7 day period whenever this is necessary for the proper performance of your duties.
		
	Holiday entitlement	  	You shall be entitled to 20 working days paid holiday in each holiday year in addition to such observed bank and Company holidays. The holiday year runs from January to December each year. Holiday entitlement must be taken at such
times and on such notice as is agreed by the Board.
		
	Sickness absence	  	You shall be entitled to receive statutory sick pay during any authorized period of absence due to illness or injury until the resumption of your duties. Your absence will only be authorized if you follow the procedures set out in
the Company’s sickness absence policy. You will not be entitled to any further payment from the Company or any Group Company (other than by way of any Statutory Sick Pay or paid statutory holiday due to you pursuant to the terms of this
Agreement) nor to the continued provision of his benefits under this Agreement until the resumption of your duties, although the Company may at the Board’s discretion continue to pay you your normal remuneration for such periods as it considers
appropriate (“Discretionary Sick Pay”)
		
	Pensions arrangements	  	See clause 3.3 above.
		
	Disciplinary and grievance procedures	  	 The Company’s disciplinary and grievance procedures as implemented from time to time will apply to your employment, with such
modifications as the Company shall deem necessary to take account of your seniority. The said disciplinary and grievance procedures shall not have contractual effect and the Company shall not be obliged to follow the procedures.

 
 The Company may, in its absolute discretion, suspend you on full pay in order to
investigate any claim or allegation which we consider could constitute serious misconduct, where relationships have broken down, where we have any grounds to consider that our property or responsibilities to other parties are at risk, and/or where
we consider that your continued presence at our premises could hinder an

  
 -16- 

			
		  	 investigation. Any such suspension is without prejudice to our right to subsequently end your employment on the same or any other ground and
will last no longer than is necessary to carry out any inquiry or investigation into the circumstances and to hold any appropriate disciplinary hearings.
  

If you wish to appeal against any disciplinary decision or decision to dismiss you, your appeal must be made in writing to the Chief Executive Officer and you
should set out in detail the reasons for your appeal.
  
 If you wish to raise a
grievance, you may do so by writing to the Chief Executive Officer in accordance with our grievance procedure. You should set out in detail the circumstances of your complaint

  
 -17- 

 EXHIBIT B 

Employee Agreement Regarding Confidential Information and Intellectual Property 

In consideration of my employment, compensation and benefits with Achieve UK Pharma Limited, its parent company Achieve Life Sciences, Inc, and all subsidiary
companies (collectively the “Company”) and for other valuable consideration, I agree as follows: 
  

	1.	I will not, without the prior written permission of the Company, disclose to anyone outside of the Company, or use in any manner, other than in connection with the business of the Company, either during or after my
employment, any Confidential Information or Material of the Company (as defined by provision 4 below), or any information or material received in confidence from third parties by the Company. If I reveal or threaten to reveal Confidential
Information, I agree that it would cause irreparable harm to the Company that could not be adequately compensated by way of a damage award, and that the Company shall be entitled to an injunction restraining me from using or disclosing such
Confidential Information, or from rendering any services to any entity to whom such Confidential Information has been or is threatened to be disclosed. The right to secure an injunction is not exclusive and the Company may pursue any other remedies
it has against me in equity or at law for a breach or threatened breach of this condition, including recovery of damages from me. This provision shall survive the termination of my employment with the Company for any reason and regardless of the
party effecting it. 

  

	2.	If I leave the employ of the Company, I will return all property of the Company in my possession or control, including but not limited to, all office equipment, and the original and copies of all files, records, emails
or other documents (whether stored on paper or electronically) as well as all Confidential Information or Material in any form without retaining any copies thereof. 

 

	3.	While employed at the Company and for the period of 1 year after the effective date of the termination of my employment at the Company for any reason and regardless of the party effecting it (the “Restricted
Period”), I will not, directly or indirectly, without the written permission of the Company, whether for my account or for the account of any other Person (excluding the Company), intentionally (i) solicit, endeavor to entice or induce any
employee or consultant of the Company to terminate his employment or relationship with the Company or accept employment or a consultant relationship with anyone else, (ii) solicit, endeavor to entice or induce any customers, clients or
potential customers or clients of the Company to terminate their relationship with the Company or (iii) interfere in a similar manner with the business of the Company. 

 

	4.	Confidential Information or Material of the Company is any information or material, whether written, oral, visual or electronic: 

  

	 	(a)	generated or collected by, or utilized in the operations of the Company that relate to the actual or anticipated business or research and development of the Company; or 

 

	 	(b)	suggested by or resulting from any task assigned to me, or work performed by me for or on behalf of the Company. 

  

	 	(c)	Confidential Information or Material of the Company includes, but is not be limited to, the Company information encompassed in all drawings, designs, drugs, medical devices, formulations, test data or results, original
writings, software in various stages of development (source code, object code, documentation, diagrams and flow charts), plans, proposals, marketing and sales plans, financial information, cost or pricing information, customer lists, trade secrets,
ideas, suppliers and other information that has value to the Company, its customers or business partners. 

  
 -18- 

	5.	I will not disclose to the Company, use in its business, bring on to the Company premises or cause the Company to use, any information or material which is confidential to others. 

 

	6.	I will comply, and do all things necessary for the Company to comply with, the laws and regulations of all governments under which the Company does business, and with provisions of contracts between any such government
or its contractors and the Company that relate to the intellectual property or to the safeguarding of information. I agree that this obligation shall survive the termination of my employment, for whatever reason and regardless of the party effecting
it. 

  

	7.	I agree that the fruits of my labor as an employee shall belong solely to the Company. To the full extent provided by law, any and all inventions, products, designs, discoveries, and work product of any nature
(collectively, the “Work Product”), whether or not patentable, copyrightable or trademarked, which I have conceived and/or made, in whole or in part, during my employment by the Company, and which have any applicability to any aspect of
the business or anticipated research or development of the Company, or the business or anticipated research or development of any of the subsidiaries of the Company, as determined by the Company, shall be the sole and exclusive property of the
Company, and by the execution hereof, I hereby irrevocably assign, transfer and convey to the Company all of my right, title and interest in and to all Work Product which may be developed during my employment by the Company. To the full extent
provided by law, any inventions or original works of authorship I conceive or create in the course of my employment shall be considered “works for hire” or works made in the course of my employment and shall belong solely and exclusively
to the Company. 

  

	  	This provision does not apply to any Work Product for which no equipment, supplies, facilities, or trade secret information of the Company was used and which was developed entirely on my own time, unless (a) the
invention relates directly to the business, or the actual or anticipated research or development of the Company, or (b) the invention results from any work performed by me for the Company. However, I agree to disclose inventions being developed
for the purposes of determining employer or employee rights. 

  

	8.	In connection with any Work Product assigned by provision 7: 

  

	 	(a)	I will promptly communicate and disclose them to the Company after such Work Product has been conceived and/or made in the detail necessary to permit the Company to understand same and practice them without the exercise
of further inventive skill; and 

  

	 	(b)	I will, on the request of the Company, promptly execute any documents necessary to effectuate the assignment of all rights to the Company, and do anything else reasonably necessary to enable the Company to secure a
patent, mask work right, copyright or other form of protection therefor in the United Kingdom and in any other foreign country. However, my failure to so execute any such documents shall in no way be deemed to affect the assignment, transfer and
conveyance of such Work Product to the Company. My obligations in this provision shall survive the termination of employment for any reason and regardless of the parties effecting it. Notwithstanding anything to the contrary in this provision, if I
believe that a specific idea or basis of a Work Product would not have any applicability to any aspect of the business or anticipated research or development of the Company, or the business or anticipated research or development of any subsidiary of
the Company, I may propose such idea or basis for Work Product in writing to the Company and request consent from the Company that such Work Product will not be subject to the provisions hereof. 

  
 -19- 

 9.      The Company and its licensees (direct or indirect) are not required to
designate me as the author or inventor of any development assigned in provision 7 when distributed publicly or otherwise, nor to make any distribution. I waive and release to the extent permitted by law all of my rights to the foregoing. 

10.    Solely for the purpose of determining my rights or the rights of the Company, I have identified on Schedule 1 hereof all
inventions, original works of authorship, developments, improvements and trade secrets that were made by me prior to my engagement by the Company or that I am currently developing. Such inventions include those which are not assigned by paragraph 7
in which I have any right, title or interest, and which were previously made or conceived solely or jointly by me, or written wholly or in part by me, and which relate to the actual or anticipated business or research or development of the Company,
but neither published nor filed in any patent office. If I do not have any to identify, I have written “none” on this line:
None                     

11.    For purposes of enforcing this Agreement, I hereby consent to jurisdiction of England and Wales courts. 

12.    If any legal action is necessary to enforce this Agreement, the prevailing party shall be entitled to recover attorneys’ fees.

 13.    This Agreement does not guarantee me any term of employment, or limit the right of the Company to terminate my employment at
any time with or without cause. 
 14.    If, for any reason, any provision of this Agreement is held invalid, such provision and all
other provisions of this Agreement shall remain in effect to the fullest extent permitted by law. If this Agreement is held invalid or cannot be enforced, then to the full extent permitted by law any prior agreement between the Company (or any
predecessor thereof) and I shall be deemed reinstated as if this Agreement had not been executed. 
 15.    This Agreement represents
the full and complete understanding between me and the Company with respect to the matters set forth herein and supersedes all prior representations and understandings, whether oral or written. My obligations under this Agreement shall be binding
upon my heirs, executors, administrators or other legal representatives or assigns, and this Agreement shall inure to the benefit of the Company, its successors and assigns. This Agreement may not be modified, released or terminated, in whole or in
part, except by an instrument signed in writing by an officer of the Company. 
  

									
					
	Signed:	 	/s/ Anthony Clarke	 		 	Dated:	 	May 22, 2018

  

									
					
	Name:	 	Anthony Clarke	 		 		 	

 Achieve UK Pharma Limited 

									
					
	Signed:	 	/s/ Richard Stewart	 		 	Dated:	 	May 22, 2018

  

									
					
	Title:	 	Chairman & CEO	 		 		 	

  
 -20- 

 Schedule 1 

Excluded Prior Developments Which Relate 

to the Actual or Anticipated Business or 

Research or Development of Achieve Life Sciences Technologies Inc. 

  
 -21-Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of May 18, 2018 (the “Effective Date”) by and among
IWeb Inc., a Nevada corporation (the “Company”), and Mang Hon WONG (including his successors and assigns, the
“Purchaser”).

 

 RECITALS

 

WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section
5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulations S thereunder, the Company desires to issue and
sell to the Purchaser, and the Purchaser desires to purchase from the Company, certain securities of the Company as more fully
described in this Agreement.

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1       Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in, and construed, under Rule 405 under the Securities Act.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii)
the Company’s obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than
June 30, 2018.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“DWAC”
shall have the meaning ascribed to such term in Section 2.2(a)(ii).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

 

    1 

     

    

 

“Exchange
Rules” shall mean the listing rules of The OTCQB Marketplace.

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Per
Share Purchase Price” equals $1.00 per share of Common Stock, subject to adjustment for reverse and forward stock splits,
stock combinations and other similar transactions of the Common Stock that may occur after the date of this Agreement.

 

“Person”
means an individual, corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(c).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(f).

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Securities
Laws” means, collectively, the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley”), the Securities
Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors
of “issuers” (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board,
the Exchange Rules and applicable state securities laws and regulations.

 

“Shares”
means an aggregate of 1,000,000 shares of Common Stock to be issued to the Purchasers pursuant to this Agreement (the “Shares”).

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

“Subscription
Amount” means, an aggregate amount of $1,000,000 to be paid for Shares purchased by the Purchaser in United States dollars
and in immediately available funds.

 

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the OTCQB or NASDAQ (or any successors to any of the foregoing).

 

“Transaction
Documents” means this Agreement, and any other documents or agreements executed between the Company and the Purchaser
in connection with the transactions contemplated hereunder.

 

“Transfer
Agent” means Action Stock Transfer, the current transfer agent of the Company, with a mailing address of 2469 E. Fort
Union Blvd., Suite 214, Salt Lake City, Utah 84121, and any successor transfer agent of the Company.

 

    2 

     

    

  

ARTICLE II.

PURCHASE AND SALE

 

2.1       Closing.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchaser agrees to purchase, up to an
aggregate of $1,000,000 of Shares. Upon receiving the Purchaser’s Subscription Amount on the Closing Date and the delivery
by the Company and the Purchaser of the other items set forth in Section 2.2 deliverable at the Closing, the Company shall deliver
to the Purchaser his Shares as determined pursuant to Section 2.2(a).

 

2.2       Deliveries.

 

(a)       On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser each of the following:

 

(i)       this
Agreement duly executed by the Company;

 

(ii)      subject
to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via paper Stock Certificate or The Depository Trust Company Deposit or Withdrawal at Custodian
system (“DWAC”) Shares equal to the Purchaser’s Subscription Amount divided by the Per Share Purchase
Price, registered in the name of the Purchaser.

 

(b)       On
or prior to the Closing Date, the Purchaser shall deliver or cause to be delivered to the Company, as applicable, the following:

 

(i)       this
Agreement duly executed by the Purchaser; and

 

(ii)      the
Purchaser’s Subscription Amount by wire transfer to the bank account directed by the Company.

 

2.3       Closing
Conditions.

 

(a)       The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)       the
accuracy when made and on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date); 

 

(ii)      all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and

 

(iii)     the
delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement on or prior to the Closing Date.

 

    3 

     

    

  

(b)       The
respective obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being
met:

 

(i)       the
accuracy when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they will be accurate as of such date); 

 

(ii)      all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed; 

 

(iii)     the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement on or prior to the Closing Date; and

 

(iv)     there
shall have been no material adverse effect with respect to the Company since the date hereof.

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

 

3.1       Representations
and Warranties of the Company. Except as indicated in the SEC Reports, the Company hereby represents and warrants to the Purchaser
as of the date of this Agreement and as of the Closing Date as follows:

 

(a)       Organization
and Qualification. The Company and each of the Subsidiaries, if any, is an entity duly incorporated or otherwise organized
and validly existing under the laws of each jurisdiction in which it owns or leases properties or conducts any business so as to
require such qualification, with the requisite power and authority to own and use its properties and assets and to carry on its
business as currently conducted.

 

(b)       Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith
or therewith other than in connection with the Required Approvals (as defined below).

 

(c)       Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any Governmental Authority or any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents
or the offer, issue and sale of the Shares, other than: (i) the disclosure filings required for this Agreement, (ii) such filings
as are required to be made under applicable state securities laws, and (iii) such consents, waivers and authorizations that shall
be obtained prior to the Closing (collectively, the “Required Approvals”).

 

(d)       Authorization
of the Shares; Registration. The Shares to be sold by the Company and their issue and sale are duly authorized and, when issued
and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and free and
clear of all Liens imposed by the Company.

 

    4 

     

    

  

(e)       Capitalization.
Except as may be described in the SEC Reports, all of the issued share capital of the Company has been duly and validly authorized
and issued, is fully paid and non-assessable.

 

(f)       SEC
Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, any such documents voluntarily filed by the Company with the Commission, including the exhibits thereto, documents incorporated
by reference therein, being collectively referred to herein as the “SEC Reports”).

 

(g)       Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not
be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

3.2       Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants as of the date hereof and as of the Closing
Date to the Company as follows (unless as made of a specific date stated therein, in which case they shall be accurate as of such
date):

 

(a)       Organization;
Authority. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out his obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by the Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of the Purchaser. Each Transaction
Document to which he is a party has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against him in accordance
with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

(b)       Understandings
or Arrangements. The Purchaser is acquiring the Shares for his own account and has no direct or indirect arrangement or understandings
with any other persons to distribute or regarding the distribution of the Shares (this representation and warranty not limiting
the Purchaser’s right to sell the Shares in compliance with applicable federal and state securities laws). The Purchaser
is acquiring the Shares as principal, not as nominee or agent, and not with a view to or for distributing or reselling the Shares
or any part thereof in violation of the Securities Act or any applicable state securities law.

 

(c)       Foreign
Investors. The Purchaser hereby represents that he has satisfied himself as to the full
observance by the Purchaser of the laws of its jurisdiction applicable to the Purchaser
in connection with the purchase of the Shares or the execution and delivery by the Purchaser of this Agreement and the Transaction
Documents, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign
exchange restrictions applicable to the purchase, (iii) any governmental or other consents that may need to be obtained, and
(iv) the income tax and other tax consequences, if any, that may be relevant to the Purchaser’s
purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser’s subscription
and payment for, and continued beneficial ownership of, the Shares will not violate any securities or other laws of the Purchaser’s
jurisdiction applicable to the Purchaser.

 

    5 

     

    

  

(d)       Experience
of Purchaser. The Purchaser, either alone or together with his representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares,
and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment
in the Shares and, at the present time, is able to afford a complete loss of such investment.

 

(e)       Access
to Information. The Purchaser acknowledges that he has had the opportunity to review the Transaction Documents and the SEC
Reports and has been afforded (i) the opportunity to ask such questions as he has deemed necessary of, and to receive answers from,
representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of investing
in the Shares; (ii) access to information about the Company and its financial condition, results of operations, business, properties,
management and prospects sufficient to enable him to evaluate his investment; and (iii) the opportunity to obtain such additional
information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to the investment.  

 

(f)       Regulation
S. The Purchaser is a non-U.S. person (as such term is defined in Rule 902 of Regulation S under the Securities Act) and is
not acquiring the Shares for the account or benefit of a U.S. person. The Purchaser will not, within six (6) months of the date
of the transfer of the Shares to the Purchaser, (i) make any offers or sales of the Shares in the United States or to, or for the
benefit of, a U.S. person (in each case, as defined in Regulation S) other than in accordance with Regulation S or another exemption
from the registration requirements of the Securities Act, or (ii) engage in hedging transactions with regard to the Shares unless
in compliance with the Securities Act. Neither the Purchaser nor any of the Purchaser’s Affiliates or any person acting on
his/her or their behalf has engaged or will engage in directed selling efforts (within the meaning of Regulation S) with respect
to the Shares, and all such persons have complied and will comply with the offering restriction requirements of Regulation S in
connection with the offering of the Shares outside of the United States. Neither the Purchaser nor any person acting on his behalf
has undertaken or carried out any activity for the purpose of, or that could reasonably be expected to have the effect of, conditioning
the market in the United States, its territories or possessions, for any of the Purchaser’s Shares. The Purchaser agrees
not to cause any advertisement of the Purchaser’s Shares to be published in any newspaper or periodical or posted in any
public place and not to issue any circular relating to the Purchaser’s Shares, except such advertisements that include the
statements required by Regulation S, and only offshore and not in the U.S. or its territories, and only in compliance with any
local applicable securities laws. Further, any such sale of the Purchaser’s Shares in any jurisdiction outside of the United
States will be made in compliance with the securities laws of such jurisdiction. The Purchaser will not offer to sell or sell the
Purchaser’s Shares in any jurisdiction unless the Purchaser obtains all required consents, if any.

 

(g)       Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, the Purchaser has not, nor
has any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases
or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the Purchaser
first discussed the transaction with the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending on the Closing of the transaction contemplated by this Agreement. The Purchaser
has maintained the confidentiality of all disclosures made to him in connection with this transaction (including the existence
and terms of this transaction).

 

    6 

     

    

  

(h)       No
Registration. The Purchaser understands that the Shares have not been, and will not be, registered under the Securities Act
or applicable securities laws of any state or country and therefore the Shares cannot be sold, pledged, assigned or otherwise disposed
of unless they are subsequently registered under the Securities Act and applicable state securities laws or exemptions from such
registration requirements are available. The Company shall be under no obligation to register the Shares under the Securities Act
and applicable state securities laws, and any such registration shall be in the Company’s sole discretion.

 

(i)       No
General Solicitation. The Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other
communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio
or presented at any seminar or any other general solicitation or general advertisement.

 

(j)       Brokers
or Finders.  The Purchaser has not engaged any brokers, finders or agents, and the Company has not, nor will, incur, directly
or indirectly, as a result of any action taken by the Purchaser, any liability for brokerage or finders’ fees or agents’
commissions or any similar charges in connection with this Agreement.

 

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1       Reservation
of Securities. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for issuance pursuant to the Transaction
Documents in such amount as may then be required to fulfill its obligations in full under the Transaction Documents.

 

4.2       Certain
Transactions and Confidentiality. The Purchaser covenants that neither he nor any Affiliate acting on his behalf or pursuant
to any understanding with he will execute any purchases or sales, including Short Sales of any of the Company’s securities
during the period commencing with the execution of this Agreement and ending at the Closing of the transaction contemplated by
this Agreement.  The Purchaser also covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company, the Purchaser will maintain the confidentiality of the existence
and terms of this transaction.

 

4.3       Legends.
The Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Shares
other than pursuant to an effective registration statement or Rule 144, the Company may require the transferor thereof to provide
to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration
of such transferred Shares under the Securities Act. The Purchaser agrees to the imprinting, so long as is required by this Section
4.3, of a legend on all of the certificates evidencing the Shares in the following form:

 

THIS SECURITY
HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS.

 

    7 

     

    

  

THESE SECURITIES ARE BEING
OFFERED TO INVESTORS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE
SECURITIES ACT”)) AND WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES
ACT IN RELIANCE UPON REGULATION S PROMULGATED UNDER THE SECURITIES ACT. TRANSFER OF THESE SECURITIES IS PROHIBITED, EXCEPT IN ACCORDANCE
WITH THE PROVISIONS OF REGULATION S PROMULGATED UNDER THE SECURITIES ACT, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR
PURSUANT TO AVAILABLE EXEMPTION FROM REGISTRATION.  HEDGING TRANSACTIONS MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH
THE SECURITIES ACT.

 

The Purchaser agrees
that he will sell any Shares pursuant to either the registration requirements of the Securities Act, including any applicable prospectus
delivery requirements, or an exemption therefrom, and that if Shares are sold pursuant to a registration statement, they will be
sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend
from certificates representing Shares as set forth in this Section 4.3 is predicated upon the Company’s reliance upon this
understanding.

 

ARTICLE V

MISCELLANEOUS

5.1       Termination. 
This Agreement may be terminated by the Company by written notice to the other party if the Closing has not been consummated on
or before June 30, 2018; provided, however, that no such termination will affect the right of any party to sue for
any breach by any other party (or parties).

 

5.2       Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its/his advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement.

 

5.3       Entire
Agreement. The Transaction Documents, together with the exhibits contain the entire understanding of the parties with respect
to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to
such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4       Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile or email at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date
of transmission, if such notice or communication is delivered via facsimile or email on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

5.5       Amendments;
Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any
manner impair the exercise of any such right.

 

    8 

     

    

  

5.6       Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.7       Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. No party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Company and the Purchaser.

 

5.8       No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in this Section 5.8.

 

5.9       Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of Nevada, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its/his respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the Clark County, Nevada. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in Clark County, Nevada, for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it/he is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it/him under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of the Transaction Documents, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with such
action or proceeding.

 

5.10       Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Shares. The terms of this
Article V shall survive the termination of the Agreement pursuant to Section 5.1.

 

5.11       Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

    9 

     

    

  

5.12       Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable

 

5.13        Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy
at law would be adequate.

 

5.14Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.15       Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement. The English version of this Agreement, regardless of whether a translation in any other language is or will be made,
shall be the only authentic version.

 

5.16       WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature Pages Follow)

 

    10 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	COMPANY
	 
	IWEB INC.
	 
	Address for Notice:
	121/34, RS Tower, 8th Floor
	Ratchadaphisek Road, Din Daeng Sub-district, din Daeng District, Bangkok, Thailand
	TEL: +662-248-2436
	Email:	 	 	 

 

	By:	/s/ Ratanaphon
Wongnapachant	 
	 	Name: Ratanaphon Wongnapachant	 
	 	Title: Chief Executive Officer and Chairman	 

  

	Purchaser	 
	 	 	 
	By:	/s/ Mang Hon
    WONG    	 
	Name: Mang Hon WONG	 
	Address: 9/F Flat B, 98 Prince Edward Rd. W, Man Lin Building, Hong Kong
	 	 	 
	Tel:	 
	Fax:	 
	Email:	 

 

  

    11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]